Extract
Macrolides are key drugs used to treat Mycobacterium avium complex (MAC) pulmonary disease (PD) [1, 2]. Members of this complex are the most frequently isolated mycobacterial species in many countries, including Japan [3], where 93.3% of nontuberculosis mycobacterial (NTM)-PDs are due to MAC [4]. The emergence of macrolide-resistant MAC, which has likely been induced by inappropriate treatment, (e.g. macrolide-containing regimens without appropriate companion medications and macrolide monotherapy), constitutes a serious challenge to MAC-PD patients, such as prolonged treatment duration and high mortality rate [5, 6]. However, little is known about the treatment practices of MAC-PD patients, especially inappropriate nonstandard treatment. Thus, we conducted a population-based cross-sectional study to describe antibiotic use among NTM-PD patients in Japan.
Abstract
This report shows poor adherence to the recommended treatment regimen for NTM-PD patients, which may pose a potential risk for the development of macrolide resistance. The risk was highest among elderly patients, and those with rheumatoid arthritis and COPD. http://bit.ly/3aBoUzE
Acknowledgments
We would like to thank BIO Communications Inc. for preparing the dataset.
Footnotes
Conflict of interest: K. Izumi reports grants from the Japan Agency for Medical Research and Development, and the Ministry of Health, Labour and Welfare, during the conduct of the study.
Conflict of interest: K. Morimoto reports grants from the Japan Agency for Medical Research and Development during the conduct of the study; and was a coordinator of a clinical trial for Insmed outside the submitted work.
Conflict of interest: K. Uchimura reports grants from the Ministry of Health, Labour and Welfare, during the conduct of the study.
Conflict of interest: M. Ato reports grants from the Japan Agency for Medical Research and Development during the conduct of the study.
Conflict of interest: N. Hasegawa reports grants from the Japan Agency for Medical Research and Development during the conduct of the study; and was the coordinator of a clinical trial for Insmed, and received grants from Taisho-Toyama Pharmaceutical Co. Ltd and Nikon Co. Ltd, outside the submitted work.
Conflict of interest: S. Mitarai reports grants from the Japan Agency for Medical Research and Development, and the Ministry of Health, Labour and Welfare, during the conduct of the study.
Support statement: This research was supported by the Japan Agency for Medical Research and Development (AMED) (grant number: JP18fk0108043). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received April 15, 2019.
- Accepted January 12, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.